6 rezultatet
FIELD OF THE INVENTION
The present invention relates to compounds that are A.sub.1 adenosine receptor antagonists, and to their use in treating mammals for various disease states, such as asthma, diabetes, cardiac disorders, degenerative disorders of the central nervous system, and disease states
The present invention relates to the field of ophthalmology. In particular, the present invention relates to the treatment of retinal tissues. More specifically, the present invention discloses compositions and methods of using adenosine uptake inhibitors in the prevention or treatment of retinal
TECHNICAL FIELD
The present invention relates to a drug containing a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative or a pharmaceutically acceptable salt thereof as an active ingredient, which inhibits nucleoside uptake of the cells to increase an extracellular adenosine concentration and is
TECHNICAL FIELD
The present invention relates to a drug containing a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative or a pharmaceutically acceptable salt thereof as an active ingredient, which inhibits nucleoside uptake of the cells to increase an extracellular adenosine concentration and is
This is a 371 application of PCT/JP94/00229, filed Feb. 16, 1994.
TECHNICAL FIELD
The present invention relates to a drug containing a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative or a pharmaceutically acceptable salt thereof as an active ingredient, which inhibits nucleoside uptake of the
TECHNICAL FIELD
The present invention relates to a drug containing a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative or a pharmaceutically acceptable salt thereof as an active ingredient, which inhibits nucleoside uptake of the cells to increase an extracellular adenosine concentration and is